Amgen Buys Dark Blue Therapeutics to Strengthen Oncology PipelineZacks Investment Research • 01/07/26
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett FavoritesBenzinga • 01/02/26
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In JanuarySeeking Alpha • 12/27/25
Dogs of the Dow Beat the Market in 2025 — Here's the Smarter 4-Stock Play for 202624/7 Wall Street • 12/25/25
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should KnowZacks Investment Research • 12/24/25
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?Zacks Investment Research • 12/23/25
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients payWSJ • 12/19/25
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTSPRNewsWire • 12/19/25
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?The Motley Fool • 12/16/25
FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular DiseaseGlobeNewsWire • 12/12/25
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia GravisZacks Investment Research • 12/12/25